Biomarkers Market Research Reports & Industry Analysis
Biomarkers refer to genes, molecules or certain characteristics enabling to evaluate or measure pharmacologic response to therapeutic treatment, or various pathogenic or biological processes. Categorized by their utilization in different medical procedures, biomarkers facilitate decision-taking in early clinical drug development, thus helping to detect a patient’s health state. Oncology belongs within the major diseases where biomarkers are widely used.
Supported by novel product’s introductions, fresh market entrants, as well as M&As and other related activities, the world Biomarkers Market is evolving at a colossal tempo, set to be ultimately valued at just over EUR 26 billion by end-2018. Novel technologies exploited for biomarker discovery are the foremost contributors to the Biomarkers sector. North America heads the market as the most speedily growing geographic area. Major Biomarkers Market participants encompass, among others, Abbot Laboratories, Affymetrix, Agilent, Epigenomics, Celera, GE Healthcare, and DiagnoCure.
The research reports under this MarketPublishers’ Catalogue delve deep into the Biomarkers Market and its major submarkets – discovery technologies, services market, application market, and various indications. Covering various geographies, the research reports identify and examine the principal trends, opportunities, and the factors propelling or clogging the market growth. The competitive landscape with comprehensive profiles of numerous players in the global Biomarkers Industry, forecasts throwing light on the market’s future are provided in the research reports too.
... the various strategies adopted by some of the key companies in the market The report tracks and analyses key innovations and patents ... and Development Drug Formulation Forensic Application Others (DNA Fingerprinting and Others) GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY SERVICES Sample Preparation Assay ...Dec, 2013 151 pages
TechNavio recognizes the following companies as the key players in the Global Imaging Biomarkers Market: Abbott Laboratories, Affymetrix Inc., Agilent Technologies Inc ... that one of the main challenges hindering the growth of this market is the presence of poor regulatory and reimbursements systems. The current ...Nov, 2013 49 pages
... . It provides an in-depth discussion and analysis of the application of companion biomarkers to drug development and targeted therapeutics, as well as their use in clinical trials ... and marketing companion biomarkers around the world. Detailed tables and charts with sales forecasts and marketshare data are also ...Aug, 2013 356 pages
Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this ... diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of ...Sep, 2011 342 pages
... the development of biological drugs in the next few years. In recent years, China bio-pharmaceuticals industry develops rapidly, but antibody drugs lag ... products in the future. Monoclonal antibody still belongs to high-end products in China market, which mainly depends on import. In 2012, the market scale ...Aug, 2013 50 pages
... antidoies on the market are provided. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and ... subscription provides a 1-year online access to the data of the Antibody Target, Technology & Pipeline Database. Credentials to access the database will be sent ...Jul, 2013
PharmaFocus: Biomarkers in Alzheimer’s Disease Summary Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The disease has emerged as a major global health priority especially because of its rapidly ...Jun, 2013 179 pages
... (mAbs) and other immunotechnology. See forecasted sales at overall world market and submarket level. Also assess emerging trends and expected ... technological and commercial possibilities. Eight ways Next-Generation Antibody Therapeutics Market 2013-2023 helps In particular, then, our investigation gives ...Feb, 2013 164 pages
... worlds leading healthcare companies during 2012 DESCRIPTION The Biomarker Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented ... , dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you ...Jan, 2013 200 pages
... to Optimize Therapeutic Outcomes Summary GBI Research’s new report, “Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize ... the unmet needs of the conventional drug discovery process. The drivers and barriers for the biomarkers market, along with the ...Nov, 2012 87 pages
4-Antibody AG - Product Pipeline Review - 2013 Summary Global Market Direct’s pharmaceuticals report, “4-Antibody AG - Product Pipeline Review - 2013” provides data on the 4-Antibody AG’s research and development focus. The report includes information on current developmental pipeline, complete with ...Jun, 2013 21 pages
... All Play Prominent Roles Summary GBI Research in its report “Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of ... are presented. This report presents detailed overview about the endpoint used in major marketed drugs and most promising molecules under ...Jun, 2012 194 pages
... growth will be seen. Developments that are linked in the press to 'personalized medicine' are many, and can at times be confusing. But there ... (where there are products on the market) for personalized medicine technologies in the following categories: Cardiac Markers, immunoassays Cardiac Risk Markers ...Mar, 2011 430 pages
... price decline in 2011 onwards. This report details the endpoints in clinical trials for cardiovascular disorders, highlighting the five major cardiovascular ... as those related to the effectiveness of treatment as well as other factors. However, endpoint selection must take into account the need to obtain the ...Jan, 2012 152 pages
... biomarkers to enable those patients most likely to benefit from VEGF inhibition, to be identified. This report provides a review of findings to date on biomarkers associated with the use bevacizumab (Avastin®); both therapy-indicating and prognostic. The identification of therapy-indicating and prognostic ...Feb, 2013 103 pages
... and Others (miRNA Analysis and Others). The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and ... , Inc., Rules-Based Medicine, Inc., and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary ...Aug, 2011 1305 pages
... Services. You see, too, world revenues to 2023 divided into technological disciplines: Genomics Proteomics Bioinformatics Other applications. You also find ... you stay ahead. Information found nowhere else Biomarkers: Technological and Commercial Outlook 2013-2023 gives independent analysis. There you ...Jul, 2013 178 pages
... as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract ... contract document on demand. The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for ...Sep, 2013 987 pages
Product description The present Competitive Intelligence Report about Antibody Therapy of Inflammatory and Autoimmune Diseases provides a competitor evaluation in the field of antibody therapeutics used or being developed for treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis ...Dec, 2010 172 pages
... numerical order, e.g. for phase, product category or company name. Sample screenshots illustrate the database. Purchase of the subscription provides a 1-year online access to the data of the Antibody Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase. ...Nov, 2010
The report “Antibody Technology Companies 2010 – A systematic guide through the landscape of antibody technologies and their providers” provides a description and ... range of possibilities, the selection of the most robust and adequate technologies fitting fitting to the product target profile has become more ...Nov, 2010 283 pages
This report analyzes the worldwide markets for Cardiac Biomarkers in US$ Million. The market is analyzed by Location-wise (Clinical Laboratory Testing, and ... Biomedical Corp., Roche Diagnostics Corp., and Siemens Healthcare Diagnostics, Inc..Market data and analytics are derived from primary and secondary ...Oct, 2011 444 pages
... equating to US$18.9 billion, the United States leads the global market for Biomarkers. Growing at a robust compounded annual growth rate of 18.8% during the period ... the data for the market value in US$ by geographic region, biomarker discovery techniques and therapeutic area. This report profiles 52 key global ...Nov, 2013 350 pages
... research to be productive. Despite significant increases in the cost of drug discovery and drug development, the number of new NCE and biological products reaching the market has not improved. A new way of conducting research has to be found and much hope and investment is being set by Biomarkers.Aug, 2010 138 pages
This new 3-volume report provides a comprehensive analysis of the major therapy areas which are driving growth, along with a critical assessment of the companies involved. Cancer Biomarkers
The cancer biomarker market...
... to trace the exact type of cancer and to target patient-specific molecular structure. The oncology biomarkers market offers high-growth opportunities ... working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the ...May, 2010 193 pages
China's demand for monoclonal antibody has grown at a fast pace in the past decade. In the next five years, both production and demand ... environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 ...May, 2013 187 pages
... , which ultimately decreases the overall cost of the entire drug discovery and development process. On the basis of type of disease, the global ... Report This research report categorizes the global biomarkers market on the basis of discovery technology, services, applications, and disease indications. These ...Sep, 2013 327 pages